Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?

Ceri Oldreive, Nick Davies, Anna Skowronska, Marwan Cheng Kuang Kwok, Guy Pratt, Paul Moss, Michael Griffiths, Samuel J. Clokie, Malcolm Taylor, Tatjana Stankovic

Research output: Chapter in Book/Report/Conference proceedingConference contribution


Recent advances in whole genome assessment have highlighted the presence of marked intraclonal heterogeneity in chronic lymphocytic leukaemia (CLL). It has been suggested that this heterogeneity plays an important role in disease progression and that treatment may facilitate the outgrowth of CLL subclones with a high proliferative advantage. Recent years have also seen the development of a number of novel therapeutic approaches for CLL, including a range of targeted treatments as well as immunochemotherapy. Consequently, there is a need to assess the effects that various treatments have on the subclonal architecture of CLL during disease progression as any changes could potentially influence future clinical decisions. In this study a cohort of 133 CLL tumours was analysed for the mutational status of 6 genes recurrently mutated in CLL; ATM, TP53, SF3B1, MYD88, BIRC3, and NOTCH1; by deep targeted sequencing with an allele depth of 3000-5000 reads.
Original languageEnglish
Title of host publicationBlood
PublisherAmerican Society of Hematology
Publication statusPublished - 3 Dec 2015

Publication series

PublisherAmerican Society of Hematology
ISSN (Print)0006-4971


Dive into the research topics of 'Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?'. Together they form a unique fingerprint.

Cite this